Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
US$374m
ImmunoGen
Lead Manager (Follow-On)
-
US$50m
Palatin Technologies
Sole Agent (ATM)
-
US$85m
Delcath Systems
Sole Placement Agent
-
US$20m
Edesa Biotech
Sole Agent (ATM Offering)
-
Eleusis Therapeutics
Exclusive Financial Advisor (Sell side)
-
US$230m
Akero Therapeutics, Inc.
Lead Manager (Follow-On Offering)
-
US$10m
Aytu BioPharma
Joint Bookrunner (Follow-On Offering)
-
US$129m
Arcellx, Inc.
Joint Bookrunner (Follow-On Offering)
-
Panbela Therapeutics
Exclusive Financial Advisor (Buy side)
